Translational control in cancer

Nature Reviews Cancer

Volumn 10, Issue 4, 2010, Pages 254-266

  Silvera, Deborah ^a   Formenti, Silvia C ^a,b   Schneider, Robert J ^a,b  

^a Department of Microbiology ^*  (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PP 242; RAPAMYCIN; UNCLASSIFIED DRUG; WYE 132;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOGENESIS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CELL SURVIVAL; CELL TRANSFORMATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; MICROENVIRONMENT; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; RNA TRANSLATION; TRANSLATION INITIATION; TRANSLATION REGULATION; TUMOR CELL;

CELL TRANSFORMATION, NEOPLASTIC; EUKARYOTIC INITIATION FACTOR-3; HOMEOSTASIS; HUMANS; MODELS, GENETIC; NEOPLASM STAGING; NEOPLASMS; PROKARYOTIC INITIATION FACTORS; PROTEIN BIOSYNTHESIS; RIBOSOMES; RNA, MESSENGER;

EID: 77950002202     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2824     Document Type: Review

References (148)

1. Pianese, G. Beitrag zur histologie und Aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allgem. Pathol. 142, 1-193 (1896).
2. Gani, R. The nucleoli of cultured human lymphocytes. I. Nucleolar morphology in relation to transformation and the DNA cycle. Exp. Cell Res. 97, 249-258 (1976).
3. Johnson, L. F., Levis, R., Abelson, H. T., Green, H. & Penman, S. Changes in RNA in relation to growth of the fibroblast. IV. Alterations in theproduction and processing of mRNA and rRNA in resting and growing cells. J. Cell Biol. 71, 933-938 (1976).
4. Zetterberg, A., Larsson, O. & Wiman, K. G. What is the restriction point? Curr. Opin. Cell. Biol. 7, 835-842 (1995).
5. Barna, M. et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456, 971-975 (2008).
6. Getz, M. J., Elder, P. K., Benz, E. W. Jr, Stephens, R. E. & Moses, H. L. Effect of cell proliferation on levels and diversity of poly(A)-containing mRNA. Cell 7, 255-265 (1976).
7. Connolly, E., Braunstein, S., Formenti, S. & Schneider, R. J. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol. Cell. Biol. 26, 3955-3965 (2006).
8. Wek, R. C., Jiang, H. Y. & Anthony, T. G. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 34, 7-11 (2006).
9. Donze, O., Jagus, R., Koromilas, A. E., Hershey, J. W. & Sonenberg, N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 14, 3828-3834 (1995).
10. Koromilas, A. E., Roy, S., Barber, G. N., Katze, M. G. & Sonenberg, N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257, 1685-1689 (1992).
11. Tejada, S. et al. Eukaryotic initiation factors (eIF) 2α and 4E expression, localization, and phosphorylation in brain tumors. J. Histochem. Cytochem. 57, 503-512 (2009).
12. Abraham, N. et al. Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J. Biol. Chem. 274, 5953-5962 (1999).
13. Yang, Y. L. et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 14, 6095-6106 (1995).
14. Bi, M. et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24, 3470-3481 (2005).
15. Koritzinsky, M. et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 25, 1114-1125 (2006).
16. Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Rev. Cancer 8, 851-864 (2008).
17. Schewe, D. M. & Aguirre-Ghiso, J. A. Inhibition of eIF2α dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 69, 1545-1552 (2009).
18. Dong, Z. & Zhang, J. T. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit. Rev. Oncol. Hematol. 59, 169-180 (2006).
19. Zhang, L., Pan, X. & Hershey, J. W. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J. Biol. Chem. 282, 5790-5800 (2007).
20. Dong, Z., Liu, L. H., Han, B., Pincheira, R. & Zhang, J. T. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene 23, 3790-3801 (2004).
21. Dong, Z. & Zhang, J. T. EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression. Mol. Biol. Cell 14, 3942-3951 (2003).
22. Scoles, D. R., Yong, W. H., Qin, Y., Wawrowsky, K. & Pulst, S. M. Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum. Mol. Genet. 15, 1059-1070 (2006).
23. Nupponen, N. N. et al. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am. J. Pathol. 154, 1777-1783 (1999).
24. Saramaki, O. et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am. J. Pathol. 159, 2089-2094 (2001).
25. Cappuzzo, F. et al. MYC and EIF3H coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J. Thorac Oncol. 4, 472-478 (2009).
26. Shi, J. et al. Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene 25, 4923-4936 (2006).
27. Marchetti, A. et al. Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. J. Virol. 69, 1932-1938 (1995).
28. Rasmussen, S. B., Kordon, E., Callahan, R. & Smith, G. H. Evidence for the transforming activity of a truncated Int6 gene, in vitro. Oncogene 20, 5291-5301 (2001).
29. Mayeur, G. L. & Hershey, J. W. Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e). FEBS Lett. 514, 49-54 (2002).
30. Mack, D. L., Boulanger, C. A., Callahan, R. & Smith, G. H. Expression of truncated Int6/eIF3e in mammary alveolar epithelium leads to persistent hyperplasia and tumorigenesis. Breast Cancer Res. 9, R42 (2007).
31. Marchetti, A., Buttitta, F., Pellegrini, S., Bertacca, G. & Callahan, R. Reduced expression of INT-6/eIF3-p48 in human tumors. Int. J. Oncol. 18, 175-179 (2001).
32. Umar, A. et al. Identification of a putative protein profile associating with tamoxifen therapy-resistance in breast cancer. Mol. Cell. Proteomics 8, 1278-1294 (2009).
33. Zanelli, C. F. & Valentini, S. R. Is there a role for eIF5A in translation? Amino Acids 33, 351-358 (2007).
34. Jenkins, Z. A., Haag, P. G. & Johansson, H. E. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics 71, 101-109 (2001).
35. Benne, R., Brown-Luedi, M. L. & Hershey, J. W. Purification and characterization of protein synthesis initiation factors eIF-1, eIF-4C, eIF-4D, and eIF-5 from rabbit reticulocytes. J. Biol. Chem. 253, 3070-3077 (1978).
36. Kemper, W. M., Berry, K. W. & Merrick, W. C. Purification and properties of rabbit reticulocyte protein synthesis initiation factors M2Bα and M2Bβ. J. Biol. Chem. 251, 5551-5557 (1976).
37. Saini, P., Eyler, D. E., Green, R. & Dever, T. E. Hypusine-containing protein eIF5A promotes translation elongation. Nature 459, 118-121 (2009).
38. Guan, X. Y. et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 64, 4197-4200 (2004).
39. Zender, L. et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008).
40. Hanauske-Abel, H. M. et al. Detection of a sub-set of polysomal mRNAs associated with modulation of hypusine formation at the G1-S boundary. Proposal of a role for eIF-5A in onset of DNA replication. FEBS Lett. 366, 92-98 (1995).
41. Cracchiolo, B. M. et al. Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. Gynecol. Oncol. 94, 217-222 (2004).
42. Balabanov, S. et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109, 1701-1711 (2007).
43. Miluzio, A., Beugnet, A., Volta, V. & Biffo, S. Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation. EMBO Rep. 10, 459-465 (2009).
44. Rosso, P. et al. Overexpression of p27BBP in head and neck carcinomas and their lymph node metastases. Head Neck 26, 408-417 (2004).
45. Sanvito, F. et al. Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer. Cancer Res. 60, 510-516 (2000).
46. Flavin, R. J. et al. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod. Pathol. 21, 676-684 (2008).
47. Gandin, V. et al. Eukaryotic initiation factor 6 is ratelimiting in translation, growth and transformation. Nature 455, 684-688 (2008).
48. Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731-745 (2009).
49. Graff, J. R., Konicek, B. W., Carter, J. H. & Marcusson, E. G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68, 631-634 (2008).
50. Lazaris-Karatzas, A., Montine, K. S. & Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 345, 544-547 (1990).
51. Lazaris-Karatzas, A. & Sonenberg, N. The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol. Cell. Biol. 12, 1234-1238 (1992).
52. Lazaris-Karatzas, A. et al. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev. 6, 1631-1642 (1992).
53. Ruggero, D. et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Med. 10, 484-486 (2004).
54. Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337 (2004).
55. Koromilas, A. E., Lazaris-Karatzas, A. & Sonenberg, N. mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J. 11, 4153-4158 (1992).
56. Rosenwald, I. B., Rhoads, D. B., Callanan, L. D., Isselbacher, K. J. & Schmidt, E. V. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2α in response to growth induction by c-myc. Proc. Natl. Acad. Sci. USA 90, 6175-6178 (1993).
57. Mamane, Y. et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2, e242 (2007).
58. Larsson, O. et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67, 6814-6824 (2007).
59. Schneider, R. J. & Sonenberg, N. in Translational Control in Biology and Medicine (eds. Mathews, M. B., Sonenberg, N. & Hershey, J. W. B.) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2007).
60. Waskiewicz, A. J. et al. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol. Cell. Biol. 19, 1871-1880 (1999).
61. Kim, S. H., Miller, F. R., Tait, L., Zheng, J. & Novak, R. F. Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression. Int. J. Cancer 124, 2813-2828 (2009).
62. Graff, J. R. et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69, 3866-3873 (2009).
63. Wendel, H. G. et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232-3237 (2007).
64. Rahmani, M., Davis, E. M., Bauer, C., Dent, P. & Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227 (2005).
65. Liu, L. et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66, 11851-11858 (2006).
66. Noske, A. et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol. Rep. 20, 1409-1417 (2008).
67. Fan, S. et al. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol. Ther. 8, 1463-1469 (2009).
68. Coleman, L. J. et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br. J. Cancer 100, 1393-1399 (2009).
69. Salehi, Z. & Mashayekhi, F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin. Biochem. 39, 404-409 (2006).
70. Braunstein, S. et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol. Cell 28, 501-512 (2007).
71. Fukuchi-Shimogori, T. et al. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 57, 5041-5044 (1997).
72. Comtesse, N. et al. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int. J. Cancer 120, 2538-2544 (2007).
73. Bauer, C. et al. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 92, 822-829 (2001).
74. Rosenwald, I. B., Hutzler, M. J., Wang, S., Savas, L. & Fraire, A. E. Expression of eukaryotic translation initiation factors 4E and 2α is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 92, 2164-2171 (2001).
75. Silvera, D. et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Naure Cell Biol. 11, 903-908 (2009).
76. Silvera, D. & Schneider, R. J. Inflammatory breast cancer cells are constitutively adapted to hypoxia. Cell Cycle 8, 3091-3096 (2009).
77. Shuda, M. et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res. 20, 2489-2494 (2000).
78. Eberle, J., Krasagakis, K. & Orfanos, C. E. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int. J. Cancer 71, 396-401 (1997).
79. Bordeleau, M. E. et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 11 8, 2651-2660 (2008).
80. Cencic, R. et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 4, e5223 (2009).
81. Lankat-Buttgereit, B. & Goke, R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol. Cell 101, 309-317 (2009).
82. Yang, H. S. et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 23, 26-37 (2003).
83. LaRonde-LeBlanc, N., Santhanam, A. N., Baker, A. R., Wlodawer, A. & Colburn, N. H. Structural basis for inhibition of translation by the tumor suppressor Pdcd4. Mol. Cell. Biol. 27, 147-156 (2007).
84. Holcik, M. Targeting translation for treatment of cancer\a novel role for IRES? Curr. Cancer Drug Targets. 4, 299-311 (2004).
85. Jopling, C. L. & Willis, A. E. N.-myc translation is initiated via an internal ribosome entry segment that displays enhanced activity in neuronal cells. Oncogene 20, 2664-26670 (2001).
86. Spriggs, K. A. et al. Canonical initiation factor requirements of the Myc family of internal ribosome entry segments. Mol. Cell. Biol. 29, 1565-1574 (2009).
87. Chappell, S. A. et al. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene 19, 4437-4440 (2000).
88. Evans, J. R. et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 22, 8012-8020 (2003).
89. Shi, Y. et al. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res. 68, 10215-10222 (2008).
90. Holcik, M., Yeh, C., Korneluk, R. G. & Chow, T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19, 4174-4177 (2000).
91. Desplanques, G. et al. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica 94, 87-93 (2009).
92. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550-562 (2009).
93. Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nature Rev. Mol. Cell. Biol. 10, 307-318 (2009).
94. Waskiewicz, A. J., Flynn, A., Proud, C. G. & Cooper, J. A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16, 1909-1920 (1997).
95. Pyronnet, S. et al. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 18, 270-279 (1999).
96. Guertin, D. A. & Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007).
97. Lin, C. J., Malina, A. & Pelletier, J. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res. 69, 7491-7494 (2009).
98. Mavrakis, K. J. et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22, 2178-2188 (2008).
99. Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 95, 15587-15591 (1998).
100. Zhou, X. et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin. Cancer Res. 10, 6779-6788 (2004).
101. Ruggero, D. & Pandolfi, P. P. Does the ribosome translate cancer? Nature Rev. Cancer 3, 179-192 (2003).
102. Nakamura, J. L., Garcia, E. & Pieper, R. O. S6K1 plays a key role in glial transformation. Cancer Res. 68, 6516-6523 (2008).
103. Holz, M. K., Ballif, B. A., Gygi, S. P. & Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123, 569-580 (2005).
104. Dorrello, N. V. et al. S6K1-and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467-471 (2006).
105. Carayol, N. et al. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J. Biol. Chem. 283, 8601-8610 (2008).
106. Shahbazian, D. et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25, 2781-2791 (2006).
107. Maira, S. M., Stauffer, F., Schnell, C. & Garcia-Echeverria, C. PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans. 37, 265-272 (2009).
108. Choo, A. Y. & Blenis, J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8, 567-572 (2009).
109. Yu, K. et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 70, 621-631 (2010).
110. Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
111. Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
112. Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biol. 4, 648-657 (2002).
113. Avruch, J. et al. Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem. Soc. Trans. 37, 223-226 (2009).
114. Vander Haar, E., Lee, S. I., Bandhakavi, S., Griffin, T. J. & Kim, D. H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nature Cell Biol. 9, 316-323 (2007).
115. Madhunapantula, S. V., Sharma, A. & Robertson, G. P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67, 3626-3636 (2007).
116. Johnson, M. D., O'Connell, M., Vito, F. & Bakos, R. S. Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J. Neurooncol. 92, 129-136 (2009).
117. Kwiatkowski, D. J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67, 87-96 (2003).
118. Budanov, A. V. & Karin, M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451-460 (2008).
119. Braunstein, S., Badura, M. L., Xi, Q., Formenti, S. C. & Schneider, R. J. Regulation of protein synthesis by ionizing radiation. Mol. Cell. Biol. 29, 5645-5656 (2009).
120. Haines, G. K. 3rd. et al. Expression of the double-stranded RNA-dependent protein kinase (p68) in squamous cell carcinoma of the head and neck region. Arch. Otolaryngol. Head Neck Surg. 11 9, 1142-1147 (1993).
121. Haines, G. K. et al. Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 63, 289-295 (1993).
122. Haines, G. K. 3rd. et al. Interferon-responsive protein kinase (p68) and proliferating cell nuclear antigen are inversely distributed in head and neck squamous cell carcinoma. Tumour Biol. 19, 52-59 (1998).
123. Terada, T., Maeta, H., Endo, K. & Ohta, T. Protein expression of double-stranded RNA-activated protein kinase in thyroid carcinomas: correlations with histologic types, pathologic parameters, and Ki-67 labeling. Hum. Pathol. 31, 817-821 (2000).
124. Kim, S. H., Forman, A. P., Mathews, M. B. & Gunnery, S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 19, 3086-3094 (2000).
125. Haines, G. K. et al. Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues. Tumour Biol. 17, 5-12 (1996).
126. Shimada, A. et al. Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Cancer Res. 58, 4434-4438 (1998).
127. Rosenwald, I. B., Wang, S., Savas, L., Woda, B. & Pullman, J. Expression of translation initiation factor eIF-2α is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer 98, 1080-1088 (2003).
128. Wang, S. et al. Expression of eukaryotic translation initiation factors 4E and 2α correlates with the progression of thyroid carcinoma. Thyroid 11, 1101-1107 (2001).
129. Wang, S. et al. Expression of the eukaryotic translation initiation factors 4E and 2α in non-Hodgkin's lymphomas. Am. J. Pathol. 155, 247-255 (1999).
130. Rosenwald, I. B. et al. Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma. Hum. Pathol. 39, 910-916 (2008).
131. Bachmann, F., Banziger, R. & Burger, M. M. Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res. 57, 988-994 (1997).
132. Dellas, A. et al. Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer 83, 1376-1383 (1998).
133. Pincheira, R., Chen, Q. & Zhang, J. T. Identification of a 170-kDa protein over-expressed in lung cancers. Br. J. Cancer 84, 1520-1527 (2001).
134. Chen, G. & Burger, M. M. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int. J. Cancer 84, 95-100 (1999).
135. Chen, G. & Burger, M. M. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int. J. Cancer 11 2, 393-398 (2004).
136. Rothe, M., Ko, Y., Albers, P. & Wernert, N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am. J. Pathol. 157, 1597-1604 (2000).
137. Guan, X. Y. et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 61, 3806-3809 (2001).
138. Xie, D. et al. Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum. Pathol. 39, 80-86 (2008).
139. Luo, J. H. et al. Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer Sci. 100, 896-902 (2009).
140. Chen, W. et al. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol. Biomarkers Prev. 18, 400-408 (2009).
141. De Benedetti, A. & Graff, J. R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23, 3189-3199 (2004).
142. Thumma, S. C. & Kratzke, R. A. Translational control: a target for cancer therapy. Cancer Lett. 258, 1-8 (2007).
143. Bauer, C. et al. Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int. J. Cancer 98, 181-185 (2002).
144. Brass, N. et al. Translation initiation factor eIF-4γ is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum. Mol. Genet. 6, 33-39 (1997).
145. Konicek, B. W., Dumstorf, C. A. & Graff, J. R. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 7, 2466-2471 (2008).
146. Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257-267 (2007).
147. Tamburini, J. et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 11 4, 1618-1627 (2009).
148. Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nature Rev. Drug Discov. 5, 671-688 (2006).